Status:
UNKNOWN
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.
Detailed Description
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in...
Eligibility Criteria
Inclusion
- ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- RET Fusion Positive
- First Diagnosis and Treatment
- Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion
- \- Patients received antitumor treatment before
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Key Trial Info
Start Date :
March 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 24 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04322591
Start Date
March 24 2020
End Date
March 24 2025
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yongchang Zhang
Changsha, Hunan, China, 410013